cyrilzakka/clinical-trials huggingface dataset:
Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy

The investigators will attempt to improve the patient experience before colonoscopy. The investigators will provide an in-office ipad video series and an electronic web guide to help patients learn all the best ways to prepare for colonoscopy. The investigators will then follow the patients who receive this eGuide to colonoscopy and observe whether or not they enjoyed the additional access to information from their providers, and will monitor whether or not they were better prepared for their colonoscopy.

This study would assess the ability of an e-intervention in patient education and instructions during peri-procedure and procedural day visits to improve the experience of gastroenterology procedures. This study would seek to show that through this alternative educational measure, there would be an increased show rate to colonoscopy appointments, an increased preparation quality, and an increase in patient understanding and satisfaction with the colonoscopy procedure. The investigators will attempt to track procedure completion rate and polyp detection rate for individual providers.

The e-intervention would be multimodal. In the pre-procedure setting, ipad would be able to provide a viewpoint for the video education, a template for the patients (or caregivers) to send themselves links to appropriate instructions to remind them of their obligations by secure email. This e-intervention would supplement traditional printed and website accessible instructions.

Eligibility Criteria:
Inclusion Criteria:

* Undergoing Colonoscopy at Johns Hopkins
* Ages 18 to 90
* Access to email (themselves or designee)
* Access to internet outside of physician visit

Exclusion Criteria:

* Unable to consent
* Unwilling to participate
* Unable to care for themselves
in Patients With SCAD Undergoing Complex PCI, the RESPONSE Study"

Evaluation of Efficacy/Safety in Cangrelor use in patients with SCAD undergoing complex PCI.

Prospective, observational, multicenter registry.

SCAD patients routinely in the Italian centers undergo complex PCIs with pre-treatment with P2Y12 inhibitors or with P2Y12 inhibitors administration after procedure. This implies that participants receive interventions as part of routine medical care, and that researchers actually observe the effect of the intervention.

Eligibility Criteria:
Inclusion Criteria:

* Patient must be at least 65 years of age at the time of signing the Informed Consent Form
* Patient presenting with SCAD undergoing complex PCI and:

  * Type 2 Diabetes Mellitus;
  * CKD (Grade specified in CRF);
  * Complex SCAD: LMD, 3VD, bifurcation lesions, Rotablator, CTO, multiple Stents, total length of the stents must be greater than 60 mm.
* Patient is to be treated for de novo lesions located in previously untreated vessels.
* Patient must agree to undergo all required follow-up visits and data collection.

Exclusion Criteria:

* History of CABG;
* In stent restenosis;
* Patient with intolerance or contra-indications to treatment with aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, heparin, contrast media;
* Patient on chronic treatment with oral anticoagulants;
* Patient with neoplastic or rheumatic diseases;
* Use of dipyridamole, cilostazol, or anticoagulant therapy during the study period;
* Bleeding disorder
* History of an ischemic stroke or intracranial bleeding
* Intracranial vascular abnormality;
* Gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days.
* Women who are pregnant/breastfeeding or who have the potential to become pregnant during the study;
* Patient with bleeding diathesis in whom antiplatelet drug is contraindicated;
* Concomitant indication to open heart surgery
* Inability to provide written informed consent
* Enrolment in another study within 1 month
Effect of Positive End Expiratory Pressure (PEEP) on Cerebral Oxymetry During Laparoscopy

The investigators hypothesized that positive end expiratory pressure (PEEP) would increase the regional oxygen saturation (rSO2).

The investigators hypothesized that PEEP would increase the rSO2 during laparoscopic surgery by improving oxygenation.

Eligibility Criteria:
Inclusion Criteria:

* ASA PS I or II adult patient undergoing laparoscopic low anterior resection with Trendelenburg position

Exclusion Criteria:

* Patients with history of cerebrovascular disease, coronary occlusive disease and/or obesity (body mass index \> 30) were excluded from this study.
Virtual Biopsy Development to Identify Patient's Glioma Grade at the CHU of Poitiers Using Magnetic Resonance Imaging

Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.


Eligibility Criteria:
Inclusion Criteria:

* Age≥ 18 years,
* Patient with suspected glioma with prior imaging
* Subject free, with legal protection guardianship or curatorship;
* Enrollment in the French Social Security system;
* Informed consent signed by the patient

Exclusion Criteria:

* Any contraindication to an MRI examination
* Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations
* Pregnant or lactating women, women of childbearing age who do not have effective contraception
Comparison Between Recombinant Versus Urinary hCG for Ovulation Induction in High Responders

The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.

Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.

Eligibility Criteria:
Inclusion Criteria:

* At least 14 follicles \>11mm on the day of triggering final oocyte maturation
* Pretreated with GnRH antagonist protocol

Exclusion Criteria:

* Poor responders
* Women with 25 or more follicles on the day of trigger
War on Melanoma™ Public Health & Education Campaign

This trial studies how well a health educational campaign works in increasing early detection of melanoma in Oregon. The health educational campaign may provide information to help people learn about the early signs of melanoma. Increased education in Oregon may decrease the number of people who die from melanoma and increase the number of melanomas that are identified at an earlier stage.

PRIMARY OBJECTIVES:

I. To measure the change in melanoma literacy in Oregon, Washington, and Utah over five years (relative to baseline) and determine if there is a statistically significant difference in literacy in Oregon (where the educational campaign occurred) as compared to the non-participating states (Washington and Utah).

II. To determine if there is an association between melanoma literacy and 1) stage at diagnosis, 2) tumor depth, 3) incidence, and 4) mortality rates in Oregon, Washington, and Utah.

III. To determine if the cost of care for melanoma in Oregon is impacted by melanoma literacy and/or tumor stage.

OUTLINE:

MEDIA CAMPAIGN: Participants view digital media strategies.

PRIMARY CARE PROVIDERS AND PROFESSIONALS: Primary care providers and professionals who see skin and potential melanomas receive online based curriculum on melanoma. Participants also complete a survey to assess knowledge and confidence before and after receiving the curriculum.

MELANOMA COMMUNITY REGISTRY VOLUNTEERS: Melanoma Community Registry volunteers in Oregon receive educational and training materials on melanoma. Participants also complete a survey before and after receiving educational material.

HIGH SCHOOL STUDENTS: High school students receive an educational lecture over 1 hour on sun-safety and early detection of melanoma practices. Participants also complete a survey before and after the educational lecture.

Eligibility Criteria:
Inclusion Criteria:

* Individuals, melanoma patients, skin service providers and health care providers interested in awareness and educational campaign

Exclusion Criteria:

* No one will be intentionally excluded
360 Degrees Virtual Reality-based Mirror Therapy for Stroke Patients

The goal of this randomized controlled trial is to compare the effects of 360 degree virtual reality-based mirror therapy (360MT) to traditional mirror therapy (TMT) and conventional physical therapy (control group) on upper extremity function among stroke patients.

The main questions it aims to answer are:

* Would 360MT be more effective when treated for 4 weeks in outcome measure ments including: Fugl-Meyer Assessment for upper extremity (FMA-UE); manual function test (MFT); and box \& block test (BBT)?
* How would particants' experience be in terms of satisfactory and enjoyment during 360MT?

The study will have three groups of participants who will be involved in different tasks:

* 360MT group: will receive mirror therapy using a virtual reality device (HMD) and perform tasks with their paralyzed hand. Sessions will last 30 minutes, 3 times a week for 4 weeks.
* TMT group: will receive mirror therapy using an acrylic mirror and perform finger, wrist, elbow exercises using their paralyzed limb. Sessions will last 30 minutes, 3 times a week for 4 weeks.
* Control group: will receive conventional physical therapy consisting of exercises for the upper extremity, 60 minutes per day, 5 sessions a week, for 4 weeks.


Eligibility Criteria:
Inclusion Criteria:

* who have not passed 12 months since onset;
* who can understand and follow instructions;
* who have ≥21 scores in Korean version of Mini-Mental State Examination (MMSE-K);
* who have mild to moderate motor impairment according to the Fugl Meyer Assessment (FMA) scores

Exclusion Criteria:

* patients who have any kinds of mental disorder and/or Alzheimer's disease;
* who have orthopedic and/or musculoskeletal injury;
* who have apraxia; and
* who have previous experiences of participating in investigations and/or mirror therapy.
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

The primary objective of the study was to assess the effect of gefitinib on the pharmacokinetics of apatinib mesylate in lung cancer patients.

The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.


Eligibility Criteria:
Inclusion Criteria:

1. 18-75 years of age.
2. ECOG performance status: level 0\~1;
3. Anticipated life expectancy ≥ 12 weeks;
4. Lung cancer patients;
5. Major organs in good function;
6. Agree to take approved method of contraception during the clinical trail and 8 weeks after the last dose of apatinib. Female subject should be negative in the pregnancy test;
7. Able to comprehend and willing to sign an informed consent form (ICF)

Exclusion Criteria:

1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients;
2. Squamous cancer, small-cell lung cancer;
3. Symptomatic central nervous system (CNS) metastases
4. Hypertension and couldn't be controlled with medicine;
5. Coagulation disorders;
6. Clinical significant bleeding in 3 months prior dosing;
7. Had surgery in four weeks prior dosing;
8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea and intestinal obstruction;
9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months prior dosing;
10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours;
11. Active infection and need antimicrobial treatments;
12. History of psychiatric substance abuse;
13. Take any clinical trial drugs within four weeks prior dosing;
14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and CYP2D6;
15. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or combined with syphilis infection;
16. Addicted to alcohol and tobacco;
17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and alcohol in 48 hours prior dosing;
18. The investigator believes that the subjects are not eligible to participate in this trial.
University Student Intervention to Increase Organ Donation

The purpose of this study is to determine the effect of brief organ donation video interventions on consent for organ donation among college and university students. Our hypothesis is that the organ donation video interventions will be superior to lay health websites for increasing organ donation consent.

This randomized controlled trial will involve 600 intervention and 600 control university students. Students will be randomized to 1 of 3 arms: a 5-minute video by the U.S. Department of Health and Human Services, a 5-minute video by the study principal investigator, or a health-related website by the Centers for Disease Control. After viewing the intervention, participants will be asked questions including whether they would like to consent to organ donation on their state electronic registry.

Eligibility Criteria:
Inclusion Criteria:

* Currently enrolled student
* English speaking
* No severe visual or auditory impairment
* Citizen of the United States of America
* Not a currently registered organ donor
* Has a driver's license, state identification card, or learner's permit from one of the 50 states

Exclusion Criteria:

* Not a currently enrolled student
* Limited English proficiency
* Severe visual or auditory impairment
* Registered organ donor
* Does not have an active driver's license, state identification card, or learner's permit from one of the 50 states
Hill-Rom WAVE for Positional Obstructive Sleep Apnea at Home

1. Determine the effects of a mattress support (Wave 4.3) that promotes the avoidance of supine airway position at home on the apnea-hypopnea index (AHI) in patients with positional obstructive sleep apnea (OSA).
2. Determine the effects of Wave 4.3 on subjective measures of sleepiness and daytime function in patients with positional OSA.
3. Determine the effects of Wave 4.3 on subjective measures of sleep quality in patients with positional OSA.

This is a preliminary single-arm study. The study will last up to 4 weeks including the screening period. Subjects will sleep using the mattress support at home for two consecutive weeks.

Outcome measures will include: AHI derived from HSAT (primary outcome), oxygen desaturation index (ODI), Epworth Sleepiness Scale (ESS) score, Functional Outcomes of Sleep Questionnaire (FOSQ), Visual Analog Scale (VAS) and questionnaire assessments of sleep quality, and actigraphic sleep measures. Subjects will also keep a sleep diary every night for the duration of the study. Subjects will be asked about their bed partners' report on snoring and witnessed apneas.

Eligibility Criteria:
Inclusion Criteria:

* • 18-75 years of age

  * Willing and able to give informed consent
  * Able to speak and understand English
  * Previous sleep study prior to enrollment done based on previous clinical evaluation by the subject's treating physician in the course of usual clinical care:

    1. overall AHI 5-40 events/hr.
    2. at least 10% time spent in the supine and 10% time in the non-supine positions.
    3. APOC I and APOC II
    4. central respiratory events \< 50% of the total number of apneas and hypopneas
  * Using at least a queen-sized mattress when sleeping at home
  * Patients who meet the above criteria who have been prescribed CPAP or dental device but are non-adherent to treatment will be enrolled in the study. CPAP non-adherence will be defined as average nightly use \< 4hrs/night based on a download of the CPAP machine, or self- acknowledged discontinuation or non-regular of CPAP use.

Exclusion Criteria:

* • Incapable of giving informed consent

  * Under the age of 18
  * Active titration of medication
  * Pregnancy, lactation (will be screened with urine pregnancy test)
  * Self-reported Substance abuse (current)
  * Excessive alcohol consumption

    * Excessive alcohol use is defined as:
    * More than 3 glasses of wine a day
    * More than 3 beers a day
    * More than 60 mL of hard liquor a day
  * Use of home oxygen
  * Presence of severe daytime sleepiness defined as an Epworth sleepiness scale score \> 16 or a prior history of falling asleep while driving
  * Presence of cardiac pacemaker or automatic implantable cardioverter-defibrillator (AICD).
  * Unstable medical problem such as uncontrolled hypertension.
  * Body Mass Index (BMI) \>45 kg/m2
  * Any other clinically significant condition that, in the opinion of the investigators, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data.
Diagnostic Accuracy of SurePath™ in EUS-FNA

It is a prospective randomized controlled study to evaluate the diagnostic accuracy of SurePath™ liquid-based cytology in endoscopic ultrasound-guided sampling.

The SurePath™ has been approved by the FDA since 1997. Investigators want to compare the diagnostic accuracy of SurePath™ liquid based cytology and conventional smear cytology(CSC) in EUS-FNA sampling of esophageal, gastric, duodenal subepithelial tumors, periesophageal and perigastric lymph nodes.

The investigators randomly assigned (1:1) patients to the SurePath™ group or the CSC group. Aspirates from the first needle pass were processed by one method, aspirates from the second pass by the other method, and specimens from the last pass were processed as core biopsy samples. The primary endpoint was the diagnostic efficacy of each method, with the final diagnosis as the gold standard. The aim of this study is to confirm that the SurePath™ is not inferior than the conventional smear test.

Eligibility Criteria:
Inclusion Criteria:

* Patients who signed the agreement after the explanation
* Patients suspected of esophageal, gastric, duodenal subepithelial tumors, periesophageal and perigastric lymph nodes from radiological(CT, MR, ultrasound) or endoscopic examinations.

Exclusion Criteria:

* Those who did not agree with the study
* Patients younger than 19 years of age
* Serious mental patients
* Patients with severe accompanying diseases (ESRD, advanced COPD, severe heart failure, sever mental illness)
* Pregnant women
* If EUS is difficult due to previous surgery (Billroth II or TG with R-en-Y)
* Patient with blood clotting abnormality
* If there is a risk of tract seeding after examination
The Effectiveness of Engagement-based Personalization of a Digital Mental Health Intervention

This study will investigate the effectiveness of an engagement-based personalized 2-week mobile wellbeing intervention, vs the effectiveness of a non-personalized 2-week mobile wellbeing intervention.


Eligibility Criteria:
Inclusion Criteria:

* at least mild depressive or anxiety complaints; \>4 Generalized Anxiety Disorder 7-item scale OR Patient Health Questionnaire 9-item scale
* access to smartphone with internet
* adequate English literacy

Exclusion Criteria:

* none
The Combination Effect of Citicoline and Omega-3

The goal of this study is to determine the effects of Citicoline plus Omega-3 or Omega-3 alone versus placebo on attention in non-demented healthy older adults.

This study is a randomized, double-blind, placebo-controlled trial. The investigators hypothesize that supplementation of Citicoline plus Omega-3 will improve attention in healthy adults age 55 years and older, compared to placebo. The study is designed as 3-arm, parallel group study comparing placebo, Omega-3 only, and Citicoline plus Omega-3.

Eligibility Criteria:
Inclusion Criteria:

* Age 55 years or older
* If female, must be post-menopausal
* Non-demented
* Not depressed
* General health status that will not interfere with the participant's ability to complete the study
* No history of neurological disorder
* Screening laboratory values within normal limits or, if abnormal, deemed clinically insignificant by the investigator
* Sufficient English language skills to complete all testing

Exclusion Criteria:

* Alzheimer's, Dementia or other neurological disease
* Fish intake of 6 ounce serving once a week 3 months prior to enrollment; Omega-3 supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 3 months prior to enrollment.
* Citicoline supplementation 3 months prior to enrollment
* Prescriptions medications:

  1. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven), Factor Xa inhibitors: rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran (pradaxa), apixaban (eliquis); Low molecular weight heparins: dalteparin (fragmin), enoxaparin (lovenox)
  2. Dementia medications (e.g. anticholinesterase inhibitors, memantine)
  3. Diagnosis of Adult Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD) and/or taking stimulants (e.g. dextroamphetamine sulfate, methylphenidate HCL, dextroamphetamine Sulf-Saccharate)
* Body Mass Index \> 30
* Enrollment in another treatment study
Surgery Versus Standardized Non-operative Care for the Treatment of Lumbar Disc Herniations: A Canadian Trial

The objective of this study is to determine if surgery is superior to non-operative care for sciatica caused by a lumbar disc herniation. This study will include patients that have had severe sciatica for greater than 4 months which reflects the wait time of the Canadian health care system. This study is an opportunity to make an important contribution to medical science as there is no "top tier" evidence for or against this highly prevalent surgery. Although there have been several recent randomized trials in the field, all have been marred by a large number of patient crossing over from non-operative to operative treatment. Due to the wait for spine surgery, the Canadian system has a built-in delay that prevents such a cross over of patients. This study capitalizes on this unique opportunity to perform a high caliber surgical trial. Patients consenting to be in the study will be randomly assigned to expedited surgery within three weeks or standardized non-operative care while they wait on the surgeons list for consultation and then surgery (minimum wait of 9 months). The study will assess pain, function, quality of life, satisfaction, and work status to determine if one treatment is superior.


Eligibility Criteria:
Inclusion Criteria:

1. 18 - 60 years old
2. Unilateral, single L5 or S1 radiculopathy (leg pain following dermatomal distribution of L5 or S1)

   * Leg dominant pain over central back pain
   * Positive straight leg raise \<70 degrees
3. MRI with corresponding L4-5 or L5-S1 posterolateral disc herniation\*
4. Radicular symptom duration greater than 4 months and less than 12 months. May be recurrent if first episode occurred within 12 months and duration of presenting episode is greater than 4 months.
5. Agree to possible discectomy

Exclusion Criteria:

1. Radiculopathy secondary to foraminal stenosis
2. Radiculopathy secondary to intra-foraminal or far lateral disc herniation
3. Radiculopathy secondary to lumbar central or lateral recess stenosis not caused by a posterolateral disc herniation
4. Previous lumbar surgery at involved level
5. Lumbar spondylolisthesis or lateral listhesis at level of disc herniation
6. Lumbar Scoliosis greater than 10 degrees